Sign in
Taking people in United StatesNo phase

Studies how cystic fibrosis medicines affect infants and young children

Follows young children with cystic fibrosis taking CFTR modulator medicines over time.

Key facts

Who runs it
Sonya Heltshe
Where
Ann Arbor, Aurora, Birmingham, Boston, Buffalo, Burlington, Charlottesville, Cincinnati, Columbus, Dallas, Fort Worth, Grand Rapids, Hershey, Houston, Indianapolis, Iowa City, Jacksonville, Kansas City, Madison, Miami, Minneapolis, New York, Oklahoma City, Orlando, Palo Alto, Philadelphia, Pittsburgh, Portland, Salt Lake City, Seattle, St Louis, Syracuse, and Valhalla, United StatesSee the 35 sites
Trial code
Registry title
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children
Status
Recruiting
People taking part
210 people, planned
Started
18 Nov 2020
Expected to end
31 Dec 2027
Type of study
Observational, 2 groups
Treatments tested
  • Ivacaftor or elexacaftor/tezacaftor/ivacaftor
Record updated
8 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for infants and children with cystic fibrosis. It studies the effects of highly effective CFTR modulator medicines. It has two parts, A and B.

Age
Part A: younger than 10 years. Part B: took part in Part A, or younger than 7 years.
Sex
All sexes can join.
Disease stage
A documented diagnosis of cystic fibrosis.
Earlier treatment
Cannot have used ivacaftor or elexacaftor/tezacaftor/ivacaftor in the 28 days before the first study visit.
Biomarker or test result
Part B: CFTR mutations that fit the FDA labeled use of ivacaftor or elexacaftor/tezacaftor/ivacaftor.

Main reasons for not taking part

  • Used an investigational drug within 28 days before the first study visit
  • Used ivacaftor or elexacaftor/tezacaftor/ivacaftor within 28 days before the first study visit
  • Used long-term oral corticosteroids within 28 days before the first study visit

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Part A:; Less than 10 years of age at the first study visit; Documentation of a CF diagnosis; Part B:
  • Participated in Part A OR less than 7 years of age at the first study visit
  • Documentation of a CF diagnosis
  • CFTR mutations consistent with FDA labeled indication of highly effective modulator therapy (ivacaftor or elexacaftor/tezacaftor/ivacaftor)
  • Physician intent to prescribe ivacaftor or elexacaftor/tezacaftor/ivacaftor

Who cannot take part

  • Use of an investigational drug within 28 days prior to and including the first study visit
  • Use of ivacaftor or elexacaftor/tezacaftor/ivacaftor within the 28 days prior to and including the first study visit
  • Use of chronic oral corticosteroids within the 28 days prior to and including the first study visit
  • Part A and Part B:

Where in United States

  • University of Michigan - Michigan MedicineAnn Arbor, United StatesContact: Dawn KruseTaking people
  • Children's Hospital ColoradoAurora, United StatesContact: Mary CrossTaking people
  • The Children's Hospital Alabama & University of Alabama at BirminghamBirmingham, United StatesContact: Heather HathorneTaking people
  • Boston Children's HospitalBoston, United StatesContact: Robert FowlerTaking people
  • The Cystic Fibrosis Center of Western New YorkBuffalo, United StatesContact: Christine RoachTaking people
  • Vermont Children's HospitalBurlington, United StatesContact: Julie SweetTaking people
  • University of VirginiaCharlottesville, United StatesContact: Erica TharringtonTaking people
  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Kelly ThorntonTaking people
  • Nationwide Children's HospitalColumbus, United StatesContact: Diana GilmoreTaking people
  • University of Texas Southwestern, Children's HealthDallas, United StatesContact: Keianna BrownTaking people
  • Cook Children's Medical CenterFort Worth, United StatesContact: Anna ReyesTaking people
  • Helen DeVos Children's HospitalGrand Rapids, United StatesContact: Andrew JamesTaking people
  • Hershey Medical Center Pennsylvania State UniversityHershey, United StatesContact: Diane M KitchTaking people
  • Baylor College of MedicineHouston, United StatesContact: Tracy MoselyTaking people
  • Riley Hospital for ChildrenIndianapolis, United StatesContact: Lisa BendyTaking people
  • University of IowaIowa City, United StatesContact: Mary TeresiTaking people
  • Nemours Children's ClinicJacksonville, United StatesContact: Jennifer (Jenn) GaffordTaking people
  • Children's Mercy Kansas CityKansas City, United StatesContact: Candy SchmollTaking people
  • University of Kansas Medical CenterKansas City, United StatesContact: Lawrence ScottTaking people
  • University of WisconsinMadison, United StatesContact: Melanie NelsonTaking people
  • University of MiamiMiami, United StatesContact: Ylber (Ivan) WhitakerTaking people
  • Children's Hospitals and Clinics of MinnesotaMinneapolis, United StatesContact: Camerone BeyTaking people
  • The Minnesota Cystic Fibrosis CenterMinneapolis, United StatesContact: Rachael BuckinghamTaking people
  • Children's Hospital of New YorkNew York, United StatesContact: Hossein SadeghiTaking people
  • Oklahoma Cystic Fibrosis CenterOklahoma City, United StatesContact: Rachael BuckinghamTaking people
  • The Nemours Children's Clinic - OrlandoOrlando, United StatesContact: Sherry WooldridgeTaking people
  • Stanford University Medical CenterPalo Alto, United StatesContact: Jacquelyn SpanoTaking people
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Erin DonnellyTaking people
  • Children's Hospital of Pittsburgh of UPMCPittsburgh, United StatesContact: Elizabeth HartiganTaking people
  • Oregon Health Sciences UniversityPortland, United StatesContact: Jenna BucherTaking people
  • Primary Children's Cystic Fibrosis CenterSalt Lake City, United StatesContact: Jane B VroomTaking people
  • Seattle Children's HospitalSeattle, United StatesContact: Sharon McNamaraTaking people
  • St. Louis Children's HospitalSt Louis, United StatesContact: Irma BauerTaking people
  • SUNY Upstate Medical UniversitySyracuse, United StatesContact: Mary ForellTaking people
  • New York Medical College at Westchester Medical CenterValhalla, United StatesContact: Zachary MesserTaking people

About the trial

What the trial wants to find out

This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children with cystic fibrosis (CF).

The 2 groups in the trial

  • Part A

    Children with CF not on ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy.

  • Part B

    Children with CF planning to start ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy. Participants from the Part A cohort of this study may enroll into the Part B cohort if they become eligible for these CFTR modulator therapies and plan to start them.

    Treatment: Ivacaftor or elexacaftor/tezacaftor/ivacaftor

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function in Infants and Young Children (BEGIN Study)
Plain-language title
Studies how cystic fibrosis medicines affect infants and young childrenGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
8 July 2026